Alstodt Lance's Form 4 filing
BioRestorative Therapies, Inc. (BRTX) · filed Jan 10, 2023
- Accession no.
- 0001567619-23-000770
- Filed
- Jan 10, 2023
- Trade date
- Jan 9, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $308. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Alstodt LanceCIK 0001756228 | Director, Officer (President, CEO, COB) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 9, 2023 | Common Stock | PPurchaseAcquired | +100 | $3.08F1 | +$308 | 186,121 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
Referenced by the price of 1 transaction in Table I.